1:00 p.m. | Registration
1:30 p.m. | Welcome Remarks
1:40 p.m. | Research fire-side chat: Recent breakthroughs in preclinical & clinical translation
- Glenn Dranoff - Global Head of Immuno-Oncology, Novartis Institutes for Biomedical Research (NIBR)
- Moderator: Uciane Scarlett - Principal, MPM Capital
2:20 p.m. | Innovation Bridge presentation: Title TBD
- Dennis Chang - Managing Partner, Clarion
- Jeffrey Bockman - EVP, Head of Oncology, Lumanity
2:50 p.m. | Innovation debate-style panel: Where is the problem – Implementation vs. Innovation?
- Barbera Webber - President & CEO, Tango Therapeutics
- David Kaufman - Partner, Third Rock Ventures
- Detlev Biniszkiewicz - CEO, NextPoint Therapeutics; Managing Director, MPM Capital
- Keith Flaherty - Professor, MGH; Co-founder Loxo Oncology, Scorpion Therapeutics
- Matt Roden - President & CEO, Aktis Oncology; Executive Partner, MPM Capital
- Otello Stampacchia - Founder, Managing Director, Omega Funds
- Moderator: Prashant Girinath - Partner, Greenberg Traurig
3:50 p.m. | People round table: Skills required to enable better translation from bench to clinic
- Loïc Vincent - CSO, Affini-T Therapeutics
- Sacha Mann - Senior Investment Director & Partner, Takeda Ventures
- Doug Fambrough - Former CEO, Dicerna Pharmaceuticals
- Leslie Williams - Co-Founder, President & CEO, hC Biosciences
- Jo Viney - Founder, President, CEO, Seismic Therapeutic
- Moderator: Luke Timmerman - Founder, Editor, Timmerman Report
4:50 p.m. | Closing Remarks
- Luke Timmerman & Life Science Cares
5:00 – 7:30 p.m. | MPM, BioImpact Capital hosted Reception